• 1
    Dunlop DD, Manheim LM, Yelin EH, Song J, Chang RW. The costs of arthritis. Arthritis Rheum 2003; 49: 10113.
  • 2
    Lacaille D. Arthritis and employment research: where are we? Where do we need to go? J Rheumatol Suppl 2005; 72: 425.
  • 3
    Kavanaugh A. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis 2005; 64 Suppl 4: iv659.
  • 4
    Kavanaugh A. The pharmacoeconomics of newer therapeutics for rheumatic diseases. Rheum Dis Clin North Am 2006; 32: 4556, viii.
  • 5
    Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol 2007; 19: 2726.
  • 6
    Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008; 8 Suppl 2: S4960.
  • 7
    Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 84955.
  • 8
    Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26: 16815.
  • 9
    Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005; 32: 187583.
  • 10
    OMERACT: Outcome Measures in Rheumatology. URL:
  • 11
    Stucki G, Boonen A, Tugwell P, Cieza A, Boers M. The World Health Organization International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. J Rheumatol 2007; 34: 6006.
  • 12
    Habib G, Artul S, Ratson N, Froom P. Household work disability of Arab housewives with rheumatoid arthritis. Clin Rheumatol 2007; 26: 75963.
  • 13
    Soderlin MK, Kautiainen H, Skogh T, Leirisalo-Repo M. Quality of life and economic burden of illness in very early arthritis: a population based study in southern Sweden. J Rheumatol 2004; 31: 171722.
  • 14
    Westhoff G, Listing J, Zink A. Loss of physical independence in rheumatoid arthritis: interview data from a representative sample of patients in rheumatologic care. Arthritis Care Res 2000; 13: 1122.
  • 15
    Van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Albada-Kuipers GA, Hofman DM, Bijlsma JW. Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br J Rheumatol 1998; 37: 84853.
  • 16
    Escorpizo R, Bombardier C, Boonen A, Hazes JM, Lacaille D, Strand V, et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007; 34: 137280.
  • 17
    Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 2006; 44: 30410.
  • 18
    Puolakka K, Kautiainen H, Pekurinen M, Mottonen T, Hannonen P, Korpela M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 2006; 65: 899904.
  • 19
    Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, der Schulenburg JM. Personal and economic burden of late- stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology (Oxford) 2008; 47: 18893.
  • 20
    Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 304654.
  • 21
    Han C, Smolen JS, Kavanaugh A, van der Heijde D, Braun J, Westhovens R, et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007; 9: R103.
  • 22
    Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42 Suppl 2: ii228.
  • 23
    Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006; 54: 71622.
  • 24
    Bejarano V, Quinn MA, Conaghan PG, Reece R, Keenan A, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008; 59: 146774.
  • 25
    Van Vollenhoven RF, Farraccioli GF, Breedveld FC, Ray S, Cifaldi M. Effect of adalimumab combination therapy on work performance: results from a companion study to PREMIER [abstract]. Ann Rheum Dis 2007; 66 Suppl 2: 192.
  • 26
    Keystone E, van der Heijde D, Mason D Jr, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two–week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 331929.
  • 27
    Smolen J, Landewe R, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. Ann Rheum Dis 2009; 68: 797804.
  • 28
    Osterhaus J, Richard L, Purcaru O. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis specific Work Productivity Survey (WPS-RA). Arthritis Res Ther 2009; 11: R73.
  • 29
    Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19: 321936.